专利检索 ap:("UNIVERSITY OF FUKUI" OR "SANTEN PHARMACEUTICAL CO., LTD.") AND inv:"Shinji TAKAOKA" 第 1 页

1.

发明申请
PROPHYLACTIC AGENT AND/OR THERAPEUTIC AGENT FOR CATARACT, MEDICINAL COMPOSITION FOR PREVENTING AND/OR TREATING CATARACT, USE OF PPAR ACTIVATOR FOR PRODUCING SAME, AND EYEDROPS 有权

公开(公告)号：US20210059997A1

公开(公告)日：2021-03-04

申请号：US16958571

申请日：2018-12-27

申请人： UNIVERSITY OF FUKUI , SANTEN PHARMACEUTICAL CO., LTD.

发明人： Masaya OKI , Fumito KANADA , Kazuma KAMATA , Yoshihiro TAKAMURA , Seiji MIYAKE , Masaru INATANI , Hiroyuki UCHIDA , Miho NOGATA , Masatomo KATO , Koushi FUJISAWA , Shinji TAKAOKA

IPC分类号： A61K31/4439 , A61K31/192 , A61K9/00 , A61P27/12 , A61K31/4406

摘要： Provided are agents for prevention and therapeutic treatment of cataract that act by a different mechanism from conventional agents, and use of a PPAR activator for production of such agents. An agent for prevention and/or therapeutic treatment of cataract, containing a PPAR activator as an active ingredient, is used.

2.

发明申请
[4-(1,3,3-TRIMETHYL-2-OXO-3,4-DIHYDRO-1H-QUINOXALIN-7-YL)PHENOXY]ETHYLOXY COMPOUND OR SALT THEREOF 审中-公开

公开(公告)号：US20190106393A1

公开(公告)日：2019-04-11

申请号：US16210163

申请日：2018-12-05

申请人： SANTEN PHARMACEUTICAL CO., LTD.

发明人： Kenji KAWASHIMA , Yusuke YAMAZAKI , Shinji TAKAOKA , Daisuke SHII , Tomoko ODA , Takahiro MATSUYAMA

IPC分类号： C07D241/44 , C07F9/6509 , A61P29/00 , A61P27/02 , C07D403/12 , A61K31/675 , A61K31/5377 , A61K31/498

CPC分类号： C07D241/44 , A61K31/498 , A61K31/5377 , A61K31/675 , A61P27/02 , A61P29/00 , C07D403/12 , C07F9/650994

摘要： The present invention relates to defined quinoxalin-2-one compounds or a pharmaceutically acceptable salt or a hydrate or a solvate thereof. The compounds, salts or hydrates have a glucocorticoid receptor agonist activity, and are useful as a medicine, in particular as a prophylactic or therapeutic agent for a glucocorticoid receptor related disease.

3.

发明申请
LIPOIC ACID PRODRUG 有权

公开(公告)号：US20220151989A1

公开(公告)日：2022-05-19

申请号：US17604054

申请日：2020-04-16

申请人： SANTEN PHARMACEUTICAL CO., LTD.

发明人： Masatomo KATO , Tomoko ODA , Shinji TAKAOKA , Takahiro HONDA , Tatsuya HATA

IPC分类号： A61K31/385 , A61K31/496 , A61K31/436 , A61K31/5377 , A61K9/00 , A61K9/08 , A61P27/10

摘要： The present disclosure provides and an agent for treating or preventing an eye disease such as presbyopia, comprising, as an active ingredient, a lipoic acid prodrug having a specified structure.

4.

发明申请
[4-(1,3,3-TRIMETHYL-2-OXO-3,4-DIHYDRO-1H-QUINOXALIN-7-YL)PHENOXY]ETHYLOXY COMPOUND OR SALT THEREOF 审中-公开

公开(公告)号：US20180244633A1

公开(公告)日：2018-08-30

申请号：US15753410

申请日：2016-08-25

申请人： SANTEN PHARMACEUTICAL CO., LTD.

发明人： Kenji KAWASHIMA , Yusuke YAMAZAKI , Shinji TAKAOKA , Daisuke SHII , Tomoko ODA , Takahiro MATSUYAMA

IPC分类号： C07D241/44 , A61P27/02 , A61P29/00 , C07D403/12 , C07F9/6509

CPC分类号： C07D241/44 , A61K31/498 , A61K31/5377 , A61K31/675 , A61P27/02 , A61P29/00 , C07D403/12 , C07F9/650994

摘要： The present invention relates to a novel [4-(1,3,3-trimethyl-2-oxo-3,4-dihydro-1H-quinoxalin-7-yl)phenoxy]ethyloxy compound or a salt thereof. The compound or a salt thereof of the present invention has a glucocorticoid receptor agonist activity, and is useful as a medicine, in particular as a prophylactic or therapeutic agent for the glucocorticoid receptor related disease.